2025 Poster Presentations

Preliminary List as of August 20

5 Prime Sciences, Inc.
From Genetic Insight to Phase 2b in Under 2 years: The 5Prime × Marea Story

AbCellera
Strategies for Tailoring T-Cell Engager Design for Solid Tumor Indications

Adimab LLC
Engineering a Panel of Potent and Developable Anti-CD3 Antibodies for Conditional Activation in the Tumor Microenvironment

Ardigen
Safer pHLA-Targeted Immunotherapies Through AI and Computational Immunology

AstraZeneca
Higher Throughput Proteomics Screens for Degrader Selectivity Profiling

AstraZeneca
Leveraging Virus-Like Particle (VLP) Technology for Antibody Discovery Against Complex Membrane Protein Targets Through In Vitro Display

Axxam
Differential Scanning Fluorimetry Screening and Biophysical Assays Identify Novel Small Molecule Binders of Pre-miR-21

Axxam
Precision Screening for Neurodegeneration: HiBiT Assay and Gene Expression in Action

Biosensing Instrument
Characterizing Binding Affinity and Avidity of Anti-HER1, Anti-HER2 and Anti-HER3 Therapeutic Antibodies in Whole Single Cells Using Label-Free Surface Plasmon Resonance Microscopy (SPRM)

BPS Bioscience, Inc.
Development of ATPase and Helicase Assays for DHX9, BLM, and WRN-Targeted Drug Discovery

BPS Bioscience, Inc.
From GLP-1 to Amylin: Development of Reporter Cell Lines for Next-Generation Metabolic Therapeutics

Bristol Myers Squibb
Implementation of Synthetic Antibody Libraries for Biotherapeutic Discovery

Carterra
Massively Parallel SPR-Based Fragment Screening of Kinase Arrays

Carterra
Selectivity and Cooperativity of PROTAC®s Using HT-SPR

Cayman Chemical Company
Fragment-Based Drug Discovery (FBDD) Approach for IRAK4

CDI Labs, Inc.
Molecular Glue/PROTAC Target ID Using HuProt Human Proteome Arrays

ChemPartner
A Novel In Vitro Platform for Evaluating Molecular Glue Degraders: Targeting VAV1 to Modulate Immune Signaling

ChemPartner
Advancing Drug Discovery Through Cytokine–Cytokine Receptor Interaction Platform

ChemPartner
Develop the Toolbox for Targeted Protein Degradation (TPD)-Based Drug Discovery

Chemspace
Approaches to Efficient Exploration of Large Combinatorial Spaces

Chemspace
Generation of Custom Synthetically Accessible Combinatorial Chemical Spaces Using Machine Learning-Based Reagent Filtering – Design of Freedom Space 4.0

Clarivate
Degraders on Target: Evaluating the Potential of this Novel Drug Class

Concept Life Sciences
Concept’s Direct to Biology (D2B) Approach to PROTAC Drug Discovery - A Streamlined Workflow for Innovative Fast Tracking of PROTACs

Concept Life Sciences
Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI

Conigen Bioscience
GPCR PAR1 or DRD2-Specific Monoclonal Antibodies Can Detect the Target Expressed on Live Cell Surfaces by Flow Cytometry

Conigen Bioscience
Recombinant Bioactive CXCR4 or CXCR5 on Virus-Like Nanoparticles Can Bind to Their Chemokine Ligand CXCL12 or CXCL13

Cube Biotech GmbH
A New Era for Full-Length Membrane Targets: From Lysate to Structure- and Assay-Ready Protein in 45 Minutes

Dalriada Drug Discovery, Inc.
iCLASS: Live-Cell Ligand Discovery Platform for “Hard-to-Drug” Protein Targets

DEL Source
Accelerating Covalent Drug Discovery with AI and Warhead Diversity for Challenging Targets

DEL Source
Enabling Hit Discovery with DEL-Pilot, Off-the-Shelf Libraries, Custom Synthesis, and Bespoke Library Pools

Domainex Ltd.
Accelerated Covalent Fragment Hit Discovery for KRAS [G12C] Using Mass Spectrometry and Direct-to-Biology Screening

Domainex Ltd.
Molecular Matchmakers: Finding the Perfect Glue

Domainex Ltd.
Using Direct-to-Biology in a Spectral Shift-PoLiPa Platform to Enable Fast Fragment Follow-Up for A2a Antagonists

Enamine Ltd.
Engineering CRBN and Applying REAL Technology for Rapid Identification of Next Generation CRBN Binders: Design and Activity Evaluation of New Molecular Glue Library and CRBN Ligand-Linker Conjugates

Eurofins Discovery
Integrated Solutions for STAT Inhibition and Targeted Protein Degradation: Enabling Novel Therapies for Cancer, Inflammation and Autoimmune Disease

Fida Biosystems
Characterization of Molecular Glues

Foghorn Therapeutics
Structural and Functional Basis of PU.1-BAF Interaction Reveals a Novel Interface for Targeting Undruggable Transcription Factors

Genovac
Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates

Ginkgo Bioworks
Automated High-Throughput ADME Assays for AI/ML in Drug Discovery

Ginkgo Bioworks
Mapping the Transcriptional Landscape of Drug Responses in Primary Human Cells Using High-Throughput DRUG-seq

Hanmi Pharmaceutical Co Ltd
HM100789, a Novel MAT2A Inhibitor, Demonstrates Antitumor Efficacy Through Synthetic Lethality in MTAP-Deficient Tumors

HitChem
Ligand-Based CRBN Molecular Glue Library: Design, Screening, and Application in Hit Discovery

ICE Bioscience
Building a TPD Discovery Platform for Autoimmune Therapeutics: From Biophysical Screening to In Vivo Validation

ICE Bioscience
Development and Application of an Integrated GPCR-Centric Screening Platform for Anti-Obesity Drug Discovery

Insitro, Inc.
ML-Driven Drug Discovery with DNA-Encoded Libraries

Japan Tobacco, Inc.
A Novel Screening and Machine Learning Method for Cytochrome P450 Induction in Early Drug Discovery Using Advanced Biomimetic Chromatography Targeting the Pregnane X Receptor

Kuano Ltd.
Advanced Quantum Methods for Next-Gen Drug Design: Unlocking Challenging Enzymes and Covalent Reactivity

Mass Dynamics
A Graph Knowledge Base for Multi-Omics Entity Mapping and Integration: Bridging Experimental and External Knowledge Layers

Massachusetts General Hospital
A CRISPR-Based Platform for Characterizing and Rescuing mRNA Splicing Mutations

MaxCyte, Inc.
Accelerating Drug Discovery with Scalable Electroporation and Assay Ready Cells

Medicines Discovery Catapult
An Analytical Platform for Rational Design of Nucleic Acid Therapeutics for Intracellular Delivery

Moffitt Cancer Center & Research Institute
A Computational Chemistry and AI-Driven Framework for Structure-Based Drug Design Informed by Underlying Factors of Mutation-Induced Drug Resistance: A Study of KRAS

Molport
Profiling the Molport In-Stock Compound Database Based on Emerging Drug Discovery Trends

NanoSyrinx Ltd.
NanoSyrinx Platform for Targeted Payload Delivery

National Institutes of Health, National Cancer Institute
Harnessing Ionizing Radiation for Spatiotemporal Control of Induced Covalent Chemistry

National Institutes of Health, National Center for Advancing Translational Sciences
Biochemical Proximity-Based Assay Profiling to Evaluate Cross-Platform Reproducibility in Identifying High-Throughput Screening Hits

Novalix
Identification of a Submicromolar BRD4 PROTAC Degrader from a Moderately Potent DEL Hit: Harnessing the Synergy of DEL and PROTAC Technologies

Nuclera
Functional Membrane Proteins - Ready in 48 Hours

Nuclera
Overcoming the Challenge of Producing Highly Disordered Transcription Factors with eProtein Discovery™

Nuvisan ICB GmbH
Discovery and Characterisation of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo Active KAT6AB Inhibitor

o2h Ltd.
ChameLogK: A Rapid, High-Throughput Assay to Assess Bioavailability of Beyond Rule of Five Compounds

Oncodesign Services
From Genes to Lead Molecules: A Workflow Tuned for Drugging Challenging Therapeutic Targets Using Fragment-Based Drug Discovery

Oxford Biotherapeutics
OGAP®-Diabetes: Proteomics-Based Target Discovery Platform for Type 2 Diabetes Mellitus

Pfizer, Inc.
High-Throughput and Cost-Effective Transcriptomics for Interrogating Compound and CRISPR Perturbations in Cells

Promega Corporation
Automation-Enabled Target Engagement Selectivity Screening of Small Molecule Kinase Inhibitors

Promega Corporation
Innovative Bioluminescence Assays for Monitoring GPCR Dynamics: Advancing Therapeutic Strategies for Metabolic Disease

Promega Corporation
Live Cell NanoBRET®-TE Assays for WRN and Synthetic Lethal Targets in the DNA Damage Response Pathway

Purdue University
Deep Learning Detects Evolutionary Patterns in the Natural Product Space

QIMA Life Sciences
Assessment of a Bi-Specific Macrophage Engager (BiME) in a Co-Injection Tumor Model for Ovarian Cancer

Reaction Biology
Apparent Potency of Small Molecule Inhibitors is Influenced By the Choice of Substrate in LIMK Biochemical In-Vitro Kinase Activity Assays

Reaction Biology
In Vitro Comparison of Kadcyla® and Enhertu® in Breast Cancer with Varying HER2 Expression: Proliferation, Internalization, Bystander Effects and Toxicity

Saint Louis University
Optimization of Nurr1 Agonists in Drug Development for Neurodegenerative Diseases

Saint Louis University
The Lonesome Orphan is Fostered: GCNF Synthetic Modulators Identified

Salipro Biotech AB
Discovery of Novel Therapeutics Against GPCRs, Ion Channels and Transporters with the Salipro® Platform

SARomics Biostructures AB
Structural Insights into Targeting IL-23 with Different Modalities

Selvita / Medicines Discovery Catapult
A Novel Approach to Target Engagement for Drug Discovery

Shinshu University
Cell-Free Preparation of Human Membrane Proteins for Structural Biology and Drug Development

Sygnature Discovery
Hide and Seek: Assessing Druggability and Uncovering Cryptic Pockets

Sygnature Discovery
Seeking New Glues: Toward a Ligase-Agnostic Platform for Molecular Glue Degrader Discovery

Tehran University of Medical Sciences
Development and Characterization of GelMA Hydrogel Containing Temozolomide and YAP siRNA Loaded in Trimethyl Chitosan-Hyaluronate Nanoparticles for Localized Drug Delivery to Glioblastoma Tumors

Transcera
Harnessing Sphingolipid Biology for the Targeted Extracellular Protein Degradation

Trilogie Bioscience
In Vitro Proximity and Ubiquitylation Assays for CRBN, VHL and Emerging Ligases of Interest in TPD

University of Illinois Chicago
Molecular Dynamics Simulations of Metabolite and Peptide Fibrils

University of Minnesota
Design of Allosteric Modulators that Change GPCR G Protein Subtype Selectivity

University of North Texas
Hit Optimization Studies in a Series of 2,5-Substituted Pyrimidine Inhibitors of Slack Potassium Channels

University of Texas at Austin
Discovery of Irreversible Ligands Targeting Functional Tyrosine and Lysine in Living Cells via Activated Sulfonate Esters

University of Texas at Austin
Selective Enhancement of Glycolysis Using a Covalent PFKL Activator

Vaccinex, Inc.
Antibody Discovery for Complex Membrane Antigens

Variational AI
Discovery of Novel Dual EGFR/FGFR1 Inhibitors via AI-Driven Design and Synthesis

Vipergen ApS
DELs in Cells – Integral Membrane Screening

Washington University
Radiometabolic Analysis for Sphingosine-1-Phosphate Receptor 1 (S1PR1) Specific PET-Radiotracers In Vivo

WuXi AppTec
Unleashing the Power of Spectral Shift Technology for Ultra-High-Throughput Binding Assays

X-Chem
Advancing Macrocyclic DNA-Encoded Libraries for Challenging Targets

X-Chem
Exploration, Exploitation and Summarization: Leveraging Thompson Sampling, Deep Data Mining and Pharmacophore Modeling to Access the Wealth of DEL Data for Drug Design Acceleration

Yonsei University
Discovery and Optimization of Kv7.4 Channel (KCNQ4) Selective Activator for Treatment of Hearing Loss